Jeffrey S. Hackman
Chief Executive Officer at Fennec Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2024
2 years of board service in total across 1 board, counting each seat separately. Longest: Fennec Pharmaceuticals Inc., 2 years.
Chief executive roles
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
44.9% a year in revenue
20% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Fennec Pharmaceuticals Inc. June 10, 202699.6%
-
Fennec Pharmaceuticals Inc. June 3, 202595.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 31, 2026 | Fennec Pharmaceuticals Inc. | Grant or award | +1,159 | — | — |
| Oct 12, 2026 | Fennec Pharmaceuticals Inc. | Grant or award | +2,224 | $5.53 | $12,299 |
| Sep 30, 2026 | Fennec Pharmaceuticals Inc. | Grant or award | +1,159 | — | — |
| Aug 31, 2026 | Fennec Pharmaceuticals Inc. | Grant or award | +1,159 | — | — |
| Jul 31, 2026 | Fennec Pharmaceuticals Inc. | Grant or award | +1,159 | — | — |
| Jun 30, 2026 | Fennec Pharmaceuticals Inc. | Grant or award | +1,159 | — | — |
| May 31, 2026 | Fennec Pharmaceuticals Inc. | Grant or award | +1,159 | — | — |
| Apr 30, 2026 | Fennec Pharmaceuticals Inc. | Option exercise | +1,159 | — | — |
| Mar 31, 2026 | Fennec Pharmaceuticals Inc. | Option exercise | +16,695 | — | — |
| Mar 31, 2026 | Fennec Pharmaceuticals Inc. | Option exercise | +1,159 | — | — |
| Mar 28, 2026 | Fennec Pharmaceuticals Inc. | Option exercise | +13,943 | — | — |
| Feb 18, 2026 | Fennec Pharmaceuticals Inc. | Option exercise | +13,710 | — | — |
| May 19, 2025 | Fennec Pharmaceuticals Inc. | Open-market purchase | +13,965 | $6.99 | $97,615 |
| May 16, 2025 | Fennec Pharmaceuticals Inc. | Open-market purchase | +1,035 | $6.75 | $6,986 |
Questions about Jeffrey S. Hackman
What boards is Jeffrey S. Hackman on?
Jeffrey S. Hackman sits on the board of Fennec Pharmaceuticals Inc.
What company is Jeffrey S. Hackman the CEO of?
Jeffrey S. Hackman has been Chief Executive Officer of Fennec Pharmaceuticals Inc. since August 2024.
How long has Jeffrey S. Hackman served on boards?
Our records show at least 2 years of board service across 1 board, the earliest from 2024.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.